title: [Prevention of Bacillus Calmette-Guérin immunotherapy complications].
abstract: Bacille Calmette-Guérin (BCG) in intravesical instillations is the reference treatment for urothelial carcinoma with a high risk of progression. Compliance with this treatment is altered by its potentially serious locoregional or general side effects. Prevention of these complications requires implementing rules of good practice for the instillations. The undesirable side effects should be recognized early. Their treatment should be rapid and adapted to the patient. The results of the French randomized, placebo-controlled ITB01 study showed that the class II side effects of BCG were significantly reduced by administration of ofloxacin after each instillation of BCG. The number of class III side effects requiring antitubercular treatment was also reduced in the patients in this study who had received ofloxacin.
authors.affiliation: Service d'Urologie et de chirurgie de la transplantation, Hôpital Edouard-Herriot, 5 pl. Arsonval, Lyon, France. marc.colombel@chu-lyon.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Colombel
authors.forename: Aude
authors.initials: A
authors.lastname: Picard
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000283:Administration, Intravesical; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000075202:Contraindications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D001500:BCG Vaccine; D015242:Ofloxacin